POSTER PRESENTATION INDEX

[P1]	**Attenuated antigens by gamma rays: Safe approach to develop immune treatment for scorpion envenoming** R. Rebbouh[1], B.A. Boussag-Abib[1], L.D. Laraba-Djebari*[1], *[1]USTHB, Algeria, [2]Pasteur Institute, Algeria*
P2]	**Awareness rate and influencing factors for agreement to receive a booster dose of Tetanus-diphtheria toxoid vaccine among Thai Adults, a questionnaire-based survey** D. Pandejpong*, P. Pisalprapa, *Mahidol University, Thailand*
[P3]	**Stabilizing and adjuvanting effect of sugars on the hepatitis B vaccine** W.F. Tonnis*[1], J.P. Amorij[2], W.L.J. Hinrichs[1], H.W. Frijlink[1], *[1]University of Groningen, The Netherlands, [2]National Institute for Public Health and Environment, The Netherlands*
[P4]	**Transfer of maternal immunity promotes the immune response of offspring against hepatitis B vaccine** Z.J. Shao*, W.L. Zhang, L. Zhang, *The Fourth Military Medical University, China*
[P5]	**Immunological evaluation of a cocktail vaccine candidate against enterotoxigenic *escherichia coli*** J. Salimyan*, R. Khalesi, Z. Ehsaie, S. Nazarian, *Imam Hossein University, Iran*
[P6]	**Safety of tetanus-diphtheria-acellular pertussis vaccine (Tdap) in adults 65 years and older: A vaccine safety datalink study** H.F. Tseng*, L.S. Sy, L. Qian, *Kaiser Permanente, USA*
[P7]	**Omp25 recombinant vaccine formulation confers protection against virulent B. abortus in a single immunization dose** D. Goel*, R. Bhatnagar, *Jawaharlal Nehru University, India*
[P8]	**Effect of adding Levamisole on seroconversion response to hepatitis B virus vaccination in hemodialysis patients A single-center experience** M. Khoshnoodi*[1], H. Sanadgol[2], *[1]Shahid Beheshti University of Medical Science, Iran, [2]Zahedan University of Medical Sciences, Iran*
[P9]	**Levamisole usage as an adjuvant to hepatitis B vaccine for hemodialysis patients, yes or no? Review of evidences** M. Khoshnoodi*[1], H. Sanadgol[2], *[1]Shahid Beheshti University of Medical Science, Iran, [2]Zahedan University of Medical Sciences, Iran*
[P10]	**Safety assessment of influenza vaccines for intradermal injection.** A.J. García Rojas*, D. Núñez Gallo, M.D. Trujillo Herrera, P. Matute Cruz, P. García Castellano, J. Solís Romero, *Public Health Service, Spain*
[P11]	**Perception and acceptability of influenza vaccines for intradermal injection.** A.J. García Rojas*, D. Núñez Gallo, M.D. Trujillo Herrera, P. Matute Cruz, P. García Castellano, J. Solís Romero, *Public Health Service, Spain*
[P12]	**A genetic and pathologic study of a DENV2 clinical isolate capable of inducing encephalitis and hematological disturbances in mice** J.H. Amorim*[1], R.S.P. Bizerra[1], R.P. dos Santos[1,2], M.E. Sbrogio-Almeida[1], M.L. Capurro[1], L.C.S. Ferreira[1], *[1]University of São Paulo, Brazil, [2]State University of Santa Cruz, Brazil, [3]Butantan Institute, Brazil*
[P13]	**Recent trend of measles in Singapore, strategies and control measures** Y. Kita*, C. Low, J. Lim, J. Tay, P.L. Ooi, J. Cutter, *Ministry of Health, Singapore*
[P14]	**Host innate immune response to infection of human cells by pathogenic and vaccine strains of Junin Virus** C. Huang*, S. Paessler, *University of Texas Medical Branch, USA*
[P15]	**Intranasal vaccination with mucosal adjuvant - antigen hybrid protein: Vibrio vulnificus flagellin FlaB fused with tetanus toxin fragment C** T.C. Nguyen*[1], S.Y. Kim[2], C.M. Kim[1], V. Verma[1], S.E. Lee[1], J.H. Rhee[1], *[1]Chonnam National University, Republic of Korea, [2]Fraunhofer Korea CBR, Republic of Korea*
[P16]	**Oral alginate-encapsulated IPNV antigen booster enhancing both systemic and local antibody responses in Atlantic salmon** L.H. Chen*, S. Mutoloki, O. Evensen, *Norwegian School of Veterinary Science, Norway*

[P17]	**Development and validation of Clostridium difficile - hamster oral infection model - for the vaccine and anti-bacterial efficacy testing.** R. Ramachandra, *Covance Inc., USA*
[P18]	**Montanide™ ISA 71 VG: A novel adjuvant for cellular immune response in poultry vaccines** F. Bertrand*, J. Ben Arous, S. Deville, L. Dupuis, *SEPPIC, France*
[P19]	**Predivac: A bioinformatics tool for multi-epitope peptide vaccine design that effectively accounts for human ethnic diversity** P.A. Oyarzun*[1,2], J.J. Ellis[1], M. Boden[1], B. Kobe[1], *[1]University of Queensland, Australia, [2]Universidad San Sebastian, Chile*
[P20]	**Evaluation of the immune response after vaccination against streptococcus pneumoniae in children born prematurely including the influence of perinatal factors** D. Chlebna-Sokol[1], E. Szynczewska*[2], *[1]University of Lodz, Poland, [2]Public Clinic Hospital No. 4 of Medical University of Lodz, Poland*
[P21]	**Targeted passive vaccine for mastitis** E. Aizenshtein*[1], Y. Pinchasov[2], E. Morag[3], G. Leitner[4], Y. Shpanir[3], J. Pitcovski[1,5], *[1]MIGAL, Israel, [2]SIAP, Israel, [3]YAMIT, Israel, [4]Veterinary Institute, Israel, [5]Tel Hai Academic College, Israel*
[P22]	**Human as compared to veterinary vaccines—investment versus yield** J. Pitcovski[1], *[1]MIGAL, Israel, [2]Tel Hai Academic College, Israel*
[P23]	**Production of cell culture based anti- rabies vaccine in ethiopia** B. Hurisa*[1], A. mengesha[1], S. kerga[1], A. metlin[1,2], D. Bankovisky[1,3], K. Urga[1], *[1]Ethiopian Health and Nutrition research Institute, Ethiopia, [2]Centre for animal health, Russia, [3]Pankrov Plant Biologics, Russia*
[P24]	**Masking antibody with Mannosamine-Biotin adduct enable passive vaccination with cross-species antibodies** T. Gefen*, J. Vaya, S. Khatib, E. Aizenstein, J. Pitcovski, *MIGAL, Israel*
[P25]	**Preclinical Evaluation of an Experimental Batch of Cell culture Based Anti-rabies Vaccine** B. Hurisa*[1], A. Mengesha[1], S. kerga[1], B. Newayesilassie[1], A. Metlin[2], D. Bankovisky[3], *[1]Ethiopian Health and Nutrition research Institute, Ethiopia, [2]Centre for aniam Health, Russia, [3]Pokrov Plant Biologics, Russia*
[P26]	**Artificial ribonucleases as universal virus inactivating agents** E.P. Goncharova*, A.A. Fedorova, V.V. Vlassov, M.A. Zenkova, *Institute of Siberian Branch of Russian Academy of Sciences, Russia*
[P27]	**Polymer blend particles for vaccine delivery** K.K. Tran, X. Zhan, H. Shen*, *University of Washington, USA*
[P28]	**A new approach to antigen delivery using the nanoparticle templating system** A.C. Taki*, V. Bansal, P.M. Smooker, *Royal Melbourne Institute of Technology University, Australia*
[P29]	**The immune effect of CVI988/Rispens vaccine against Marek's Disease by different innoculation routes** H.M. Wang, W.X. Tian*, G.B. Ning, N. Sun, F. Li, Y. Wang, *Shanxi Agricultural University, China*
[P30]	**Elastase dependent live attenuated vaccine for swine influenza** A. Masic[1], S. Babiuk[2], Y. Zhou*[1], *[1]University of Saskatchewan, Canada, [2]Canadian Food Inspection Agency, Canada*
[P31]	***Salmonella* as a vaccine vector for influenza virus** T.T.H. Van*, Y.C. Lin, P.J. Coloe, P.M. Smooker, *RMIT University, Australia*
[P32]	**Subunit vaccine including multi-stage antigens showed high protective efficacy against Mycobacterium tuberculosis infection in mice** B.D. Zhu*[1], H.X. Niu[1], Q. Li[1], *[1]Lanzhou University, China, [2]Lanzhou Institute of Biological Products, China, [3]Johns Hopkins University, USA, [4]Wuhan University, China*
[P33]	**Design immunogens against HPAI H5N1 viruses and beyond on the basis of a comprehensive serologic study** F. Zhou*[1], G. Wang[1], P. Buchy[2], X. Wan[3], V. Deubel[2], P. Zhou[1], *[1]Chinese Academy of Sciences, China, [2]Institut Pasteur in Cambodia, Cambodia, [3]Mississippi State University, USA*
[P34]	**Increase in memory B cell response and protective efficacy against Bacillus anthracis spore challenge in mice by the CIA06B-adjuvanted anthrax protective antigen** S.R. Wui[1], J.E. Han[1], Y.H. Kim[2], N.G. Lee*[1], *[1]Sejong University, Republic of Korea, [2]Korea Centers for Disease Control, Republic of Korea*

[P35]	**Potentiation of immunity of piglets to Mycoplasma hyopneumoniae vaccine with fused gene for pig IL-4 and IL-6 embodied in chitosan nanoparticles** X. Yang[1], J.L. Chen[1], C. Chen[2], H. Zhang[1], X.P. Wan[1], R. Gao*[1], *[1]Life Science College, Sichuan University, China, [2]Bioengineering Department of Sichuan University of Science & Engineering, China*
[P36]	**Enhancement of the immunity of Piglets to Pseudorabies vaccine with plasmids containing interleukin-6 gene and CpG motifs encapsulated in chitosan nanoparticles** J. Huang[1], H. Zhang[2], J.L. Chen*[1], Y. Yang[1], X.P. Wan[1], R. Gao[1], *[1]Sichuan University, China, [2]Biology group of North Sichuan Medical College, China*
[P37]	**Transcriptome analysis of PBMC from HIV-infected individuals undergoing immunotherapy reveals major changes in mRNA expression** A.C. Andeweg[1], A.L. de Goede[1], J.L. Aerts[2], K. Thielemans[2], R.A. Gruters[1], A.D. Osterhaus*[1], *[1]Erasmus MC, The Netherlands, [2]Vrije Universiteit Brussel, Belgium*
[P38]	**Cross-neutralizingactivity among swine immunized with live-attenuated genotype iii japaneseencephalitis virus vaccine against genotype i virus** Y.C.F. Fan, J.M.C. Chen, Y.Y.C. Chen, J.W.L. Lin, S.S.C. Chiou*, *National Chung Hsing University, Taiwan*
[P39]	**Construction and expression of viral-like particle of classical swine fever virus in mammalian cells and evaluation the vaccine potency** J.W.L. Lin*, S.S.C. Chiou, *National Chung Hsing University, Taiwan*
[P40]	**Effects of Gallid Herpesvirus 2 Marek's Disease challenge virus and atteunated vaccine virus CVI988/Rispens on immune function of erythrocytes of chickens** W.X. Tian*, N. Sun, G.B. Ning, X.H. Wang, J. Feng, D.J. Zhang, *Shanxi Agricultural University, China*
[P41]	**Effects of Gallid Herpesvirus 2 Marek's Disease challenge virus and atteunated vaccine virus CVI988/Rispens on immune function of peripheral blood lymphocyte in chickens** D.J. Zhang, J. Feng, G.B. Ning, Y. Wang, W.X. Tian*, N. Sun, *Shanxi Agricultural University, China*
[P42]	**A multienvelope DNA prime Env protein boost induces functionally protective HIV antibodies** N.A. Hutnick*[1], D.J.F. Myles[1], M. Wise[1], J. Pollara[2], A. Khan[3], N.Y. Sardesai[3], *[1]University of Pennsylvania, USA, [2]Duke University Medical Center, USA, [3]Inovio Pharmaceuticals, USA, [4]New York University Medical Center, USA, [5]Novartis Vaccines and Diagnostics, USA*
[P43]	**Study on the improvement of content test for purified Vi polysaccharide vaccine** S.Y. Eum*, K.T. Nam, B.G. Kim, S.H. Hong, *Korea Food and Drug Administration, Republic of Korea*
[P44]	**Macaque infection by one virus clone from a pool of diverse SHIVenv derived from acute HIV-1 infections is not related to a defined phenotypic property** Y. Gao*[1], M. Tian[1], B. Pahar[2], B.S. Bagaya[1], E.J. Arts[1], R. Veazey[2], *[1]Case Western Reserve University, USA, [2]Tulane University, USA*
[P45]	**Cross reactivity of influenza B virus-specific cytotoxic T lymphocytes between different virus lineages** Y. Dou*[1], M.L.B. Hillaire[1], S.E. van Trierum[1], A.D.M.E. Osterhaus[1,2], G.F. Rimmelzwaan[1,2], *[1]Erasmus MC, The Netherlands, [2]Viroclinics Biosciences, The Netherlands*
[P46]	**Screening protective antigens of *Brucella* by large scale cellular immunity evaluation of virulence related proteins** Z.L. Chen*, Y.F. Wang, Y.H. Ke, X.T. Yuan, L.Y. Huang, *Academy of Military Medical Science, China*
[P47]	**Enhancement of immune responses to pandemic H1N1 influenza virus split vaccine by the adjuvant CIA06** J.I. Ryu[1], S.A. Park[1], J.E. Han[1], S.R. Wui[1], A. Ko[1], N.G. Lee*[1], *[1]Sejong University, Republic of Korea, [2]International Vaccine Institute, Republic of Korea, [3]EyeGene Inc., Republic of Korea*
[P48]	**Pyrogenicity evaluation of influenza vaccine with TLR agonists in ferret** M. Kitano*[1], T. Homma[1], K. Taniguchi[1], M. Oonishi[1], M. Kobayashi[1], A. Sato[1], T. Aoshi[2], K. Ishii[2], *[1]Shionogi & Co., Ltd., Japan, [2]National Institute of Biomedical Innovation, Japan*
[P49]	**Evaluation of an improved rapid neutralizing antibody detection test (RAPINA) for qualitative and semiquantitative detection of rabies neutralizing antibody in humans and dogs** A. Nishizono*[1], A. Kamruddin[1], P. Khawplod[2], K. Yamada[1], D. Perera[3], O. Wimalaratne[3], *[1]Oita University, Japan, [2]Thai Red Cross Society, Thailand, [3]Medical Reseach Institute, Sri Lanka*
[P50]	**Protective efficacy of crude virus-like particle vaccine against HPAI H5N1 in chickens and its application on DIVA strategy** J.K. Park*[1], D.H. Lee[1], Y.N. Lee[1], S.S. Yuk[1], J.H. Kwon[1], C.S. Song[1], *[1]Konkuk University, Republic of Korea,*

	[2]*Georgia State University, USA,* [3]*Yonsei University, Republic of Korea*
[P51]	**A survey to study on farmers (duck farm) in the awareness of local vaccine products in Perak state of Malaysia** M.A. Jaafar*, S. Mohd Yusof, R. Mohamed, *Veterinary Research Institute, Malaysia*
[P52]	**Identification and validation of peptides as subunit vaccine candidates for immunization against microfilariae of *litomosoides sigmodontis*** Z. Ding*[1,4], S. Dreher[1], S. Babayan[2], K.H. Wiesmüller[3], P. Soboslay[1], W. Hoffmann[1], [1]*Universität Tübingen, Germany,* [2]*University of Edinburgh, UK,* [3]*EMC Microcollections GmbH, Germany,* [4]*Nanjing University, China*
[P53]	**An Integrated approach to identify campylobacter proteins that interact with the chicken immune system** X. Mu*, A. Hung, B. John, P.M. Smooker, *RMIT University, Australia*
[P54]	**Immunological effect of alum vaccine adjuvant on cell differentiation** Y.W. Yang*, C.F. Chang, *National Taiwan University, Taiwan*
[P55]	**Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational self controlled case series study in Europe** D. Weibel*[1,3], S. Romio[1], P. Kramarz[2], K. Johansen[2], J. Bonhoeffer[3,4], M. Sturkenboom[1], [1]*Erasmus University Medical Center, The Netherlands,* [2]*ECDC, Sweden,* [3]*Brighton Collaboration, Switzerland,* [4]*University Children's Hospital, Switzerland*
[P56]	**Leishmania donovani nucleoside hydrolase terminal domains in cross-protective immunity to Leishmania amazonensis infection** D. Nico, D.F. Feijó, D.C. Gomes, M. Palatnik, C.B. Palatnik-de-Sousa*, *Universidade Federal do Rio de Janeiro (UFRJ), Brazil*
[P57]	**Need for collaborative international vaccine benefit-risk studies in low-income countries: a pilot project** D. Weibel*[1], S. Black[6], O. Sankoh[2], R. Chen[3], J. Bonhoeffer[4,5], M. Sturkenboom[1], [1]*Erasmus University Medical Center, The Netherlands,* [2]*INDEPTH network, Ghana,* [3]*KEMRI/CDC Research and Public Health Collaboration, Kenya,* [4]*Brighton Collaboration Foundation, Switzerland,* [5]*University Children's Hospital Basel, Switzerland,* [6]*Cincinnati Children's Hospital Medical Center, USA*
[P58]	**Background rates of Guillain-Barré syndrome in Europe: A VAESCO study** J. Dieleman[1], D. Weibel*[1], K. Johansen[2], P. Kramarz[2], J. Bonhoeffer[3,4], M. Sturkenboom[1], [1]*Erasmus MC, The Netherlands,* [2]*European Centre for Disease Prevention and Control, Sweden,* [3]*Brighton Collaboration, Switzerland,* [4]*University Children's Hospital, Switzerland*
[P59]	**The incidence of narcolepsy in Europe: Before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns** L. Wijnans[1], D. Weibel*[1,3], K. Johansen[2], P. Kramarz[2], J. Bonhoeffer[3,4], M. Sturkenboom[1], [1]*Erasmus University Medical Center, The Netherlands,* [2]*European Centre for Disease Prevention and Control, Sweden,* [3]*Brighton Collaboration Foundation, Switzerland,* [4]*University Children's Hospital, Switzerland*
[P60]	**Invasive pneumococcal disease (IPD): A prospective active surveillance in a low coverage vaccinated population** J.J. Picazo*[1], J. Dueñas[2], A. Ramirez[2], A.R. Perez[3], E. Padilla[3], S. Herrero[4], [1]*Hosp. Clinico san Carlos, Spain,* [2]*Hosp. Son Dureta, Spain,* [3]*Hosp. Manacor, Spain,* [4]*Hosp. Son Llatzer, Spain,* [5]*Pfizer, Spain*
[P61]	**enhanced strength-weakness-opportunity-threat (swot+) analysis of international vaccine safety activities (IVSA)** D. Weibel*[1,2], Y. Li[2], A. Dodoo[3], S. Shin[4], J. Bonhoeffer[2,5], [1]*Erasmus University Medical Center, The Netherlands,* [2]*Brighton Collaboration Foundation, Switzerland,* [3]*University of Ghana Medical School, Ghana,* [4]*International Vaccine Institute, Republic of Korea,* [5]*University Children's Hospital Basel, Switzerland*
[P62]	**Simplicity, brevity, and accuracy of an online passive reporting platform for adverse events following immunization in Canada** D. Weibel*[1,2], B. Law[3], J.P. Collet[4], R. Pless[3], J. Lafleche[3], J. Bonhoeffer[1,5], [1]*Brighton Collaboration Foundation, Switzerland,* [2]*Medical Informatics, The Netherlands,* [3]*Public Health Agency of Canada, Canada,* [4]*Dalhousie University, Canada,* [5]*University Children's Hospital, Switzerland*
[P63]	**mRNA signatures measured via mRNA sequencing in high/low responders to rubella vaccine** A.L. Oberg*, I.H. Haralambieva, R.B. Kennedy, D.E. Grill, I.G. Ovsyannikova, G.A. Poland, *Mayo Clinic, USA*
[P64]	**Flu vaccination coverage and influential factors among the elderly people in Japan** Y. Tsuchiya*, K. Machida, *Waseda University, Japan*

[P65]	**Evaluation of the DNA vaccine based on protein expression isolated from the genomic island 3 of *Brucella abortus*.** A. Oñate*, W. Saitz, R. Riquelme, P. Fernandez, A. Retamal, *Universidad de Concepción, Chile*
[P66]	**Medical case review of adverse events reported to public health agency of Canada for vaccines administered in 2011** B. Law*, S. Kim, J. Nkanza, H. Anyoti, J. Laflèche, N. Ahmadipour, *Public Health Agency of Canada, Canada*
[P67]	**Seizures reported to the Canadian adverse events following immunization surveillance system: 1987-2012** B. Law*, J. Laflèche, *Public Health Agency of Canada, Canada*
[P68]	**Immunogenicity of polyacrylamide gel purified VP2 protein expressed via chimeric viral transcripts infection strategy in Nicotiana benthamiana against the highly virulent Infectious Bursal Disease Virus (hvIBDV)** M.S. Hasmah*[1,3], H.S. Loh[1], F. Massawe[1], A.R. Omar[2], *[1]University of Nottingham, Malaysia, [2]University of Putra Malaysia, Malaysia, [3]University of Selangor, Malaysia*
[P69]	**Comparison of full immunization coverage using lot quality assurance sampling in Ibadan north east and Ido local government areas, Oyo state, Nigeria** A.A. Fatiregun*, R. Ayoka, *University of Ibadan, Nigeria*
[P70]	**Circumventing anti-vector immunity using AVIP for repeated applicatin of adenovirus vectored vaccines** C.J. Sun*, L.Q. Feng, Y.F. Zhang, L. Chen, *Chinese Academy of Sciences, China*
[P71]	**Preparation of indigenous live attenuated infectious bursal disease virus vaccines in Pakistan** N.A. Lone*[1], S.F. Rehmani[1,2], S.U. Kazmi[1,3], *[1]Karakoram International University, Pakistan, [2]University of Karachi, Pakistan, [3]Sindh Poultry Vaccine Center, Pakistan*
[P72]	**Construction and evaluation of an adenovirus/alphavirus replicon chimeric vectored vaccine against classical swine fever** Y. Sun*, D.Y. Tian, H.Y. Li, S. Li, H.J. Qiu, *CAAS, China*
[P73]	**Long-term semi-continuous production of recombinant E2 protein with genetically engineered baculovirus/insect cell system in two-stage rector system** J.O. Ahn*[1], M.H. Hong[1], S.S. Yoo[3], *[1]KRIBB BPED, Republic of Korea, [2]KRIBB IBRC, Republic of Korea, [3]Choong-Ang Vaccine Laboratory, Republic of Korea*
[P74]	**YscF is a highly specific marker for evaluation of antibody response to live plague vaccine in humans** V.A. Feodorova*[1], A.M. Lyapina[1,2], M.V. Telepnev[3], M.A. Khizhnyakova[1,4], S.S. Konnova[1,5], V.L. Motin[3], *[1]Saratov State Veterinary Institute, Russia, [2]Saratov State Medical University, Russia, [3]University of Texas Medical Branch, USA, [4]Saratov State Agrarian University, Russia, [5]Saratov State University, Saratov, Russia*
[P75]	**Application of quantitative gene expression analysis to the safety control of influenza vaccines** H. Momose*, T. Mizukami, M. Kuramitsu, K. Takizawa, A. Masumi, I. Hamaguchi, *National Institute of Infectious Diseases, Japan*
[P76]	**IgG isotype profile is critical in the protection of a DNA vaccine encoding envelope protein of Japanese encephalitis virus** C.H. Pan*[1,2], H.M. Hu[1], H.W. Chen[1], *[1]National Health Research Institutes, Taiwan, [2]China Medical University, Taiwan, [3]Academia Sinica, Taiwan*
[P77]	**Induction of the activation of innate and adaptive immunity by lipidated peptide vaccine: Robust and enduring protection against Mycobacterium tuberculosis** J.N. Agrewala*[1], U. Gowthaman[1], V. Singh[1], W. Zeng[2,1], U.D. Gupta[3,1], D.C. Jackson[2,1], *[1]Institute of Microbial Technology, India, [2]The University of Melbourne, Australia, [3]3Central JALMA Institute for Leprosy and Other Mycobacterial Diseases, India*
[P78]	**Induction of antigen-specific regulatory T-cells by DNA vaccines encoding DC-targeted antigens** T. Niezold*[1], M. Storcksdieck genannt Bonnsmann[1], W. Hansen[2], K. Überla[1], M. Tenbusch[1], *[1]Molecular and Medical Virology, Germany, [2]Institute of Medical Microbiology, Germany*
[P79]	**Designing and expression of a new fusion protein as a dengue virus vaccine candidate** H. Fahimi*, M. Mohammadipoor, M. Sadeghizadeh, *Tarbiat Modares University, Iran*
[P80]	**Chaperonin GroEL: a novel phylogenetically conserved protein with strong immunoreactivity of Avian Path ogenic Escherichia coli isolates from duck identified by immunoproteomics** Y.L. Bao*, Z.P. Zhai, S.H. Wang, J.L. Ma, W. Zhang, C.P. Lu, *Nanjing Agricultural University, China*

[P81]	**Targeting Salmonella lipopolysaccharide to develop a universal vaccine against enteric bacteria** Q. Kong*, R. Curtiss, *Arizona State University, USA*
[P82]	**HPV-16 E6 and E7 protein T cell epitopes prediction analysis based on distributions of HLA-A loci across populations: An in silico approach** Y.F. Yao*, Y.C. Che, W.W. Huang, L. Shi, X. Yang, W.J. Sun, *Chinese Academy of Medical Sciences & Peking Union Medical College, China*
[P83]	**Targeting TLR7/8 receptors on monocyte-derived dendritic cells to induce potent anti-HBs immune responses in HBV transgenic mice** Y. Wang[1], Z. Wu[1], K. Chen[1], G. Liu[2], C. Qu*[1], *[1]Chinese Academy of Medical Sciences, China, [2]458th Hospital, China*
[P84]	**EV71-infected CD14$^+$ cells modulate the immune activity of T lymphocytes in rhesus monkeys** J.W. Wang*, J. Pu, Y. Zhang, L.D. Liu, E.X. Yang, Q.H. Li, *Institute of Medical Biology, CAMS, China*
[P85]	**Isolation, preparation and evaluation of the immunogenicity effectiveness of a novel inactivated rotavirus vaccine strain: ZTR-68, rotavirus A genotype G1P[8]** H.J. Li*[1], J.Y. Wu[1], S. Yi[1], G.M. Zhang[1], G.F. Mu[2], L. Xie[1], *[1]Chinese Academy of Medical Science and Peking Union Medical College, China, [2]The First People's Hospital of Zhaotong City, China*
[P86]	**Booster and catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in children in Nigeria** O.O. Odusanya*[1], Y.A. Kuyinu[1], O.A. Kehinde[1], F. Shafi[2], N. François[3], J.P. Yarzabal[3], *[1]Lagos State University College of Medicine, Nigeria, [2]GlaxoSmithKline Pharmaceuticals, India, [3]GlaxoSmithKline Vaccines, Belgium*
[P87]	**Immunotherapy against Leishmania (L.) amazonensis infection With nucleoside hidrolase (NH36) peptides of Leishmania (L.) amazonensis** D. Nico, D.F. Feijó, D.C. Gomes, M. Palatnik, C.B. Palatnik-de-Sousa*, *Universidade Federal do Rio de Janeiro, Brazil*
[P88]	**Immunotherapy against visceral Leishmaniasis with nucleoside hidrolase peptides of Leishmania (L.) donovani** D. Nico, D.F. Feijó, D.C. Gomes, M. Palatnik, C.B. Palatnik-de-Sousa*, *Universidade Federal do Rio de Janeiro, Brazil*
[P89]	**Immunization with the C-Terminal domain peptides of Leishmania (L.) donovani nucleoside hydrolase (NH36) aiming the identification of main epitopes** D. Nico[1], M.M. Rodrigues[2], M. Palatnik[1], C.B. Palatnik-de-Sousa*[1], *[1]Universidade Federal do Rio de Janeiro, Brazil, [2]Universidade Federal de São Paulo, Brazil*
[P90]	**Development of a novel humanized HLA-A2.1/DP4 transgenic mouse model and its application for HLA-DP4 restricted epitopes mapping** Z.T. Ru*[1,2], S.H. Sun[1], Z.H. Kou[1], G.Y. Zhao[1], Y.C. Lone[2], Y.S. Zhou[1], *[1]Beiijng Institute of Microbiology and Epidemiology, China, [2]Université Paris-Sud &Hôpital Paul Brousse, France*
[P91]	**Newcastle disease virus-vectored Nipah encephalitis vaccines induce B and T cell responses in mice and long-lasting neutralizing antibodies in pigs** D. Kong[1,2], Z. Wen*[1], H. Su[1], J. Ge[1], W. Chen[1], X. Wang[1], *[1]Chinese Academy of Agricultural Sciences, China, [2]Emory University School of Medicine, USA*
[P92]	**The studies on the co-adjuvant effects of heparan sulfate and zinc hydroxide and the mechanism of heparin sulfate adjuvant** M.N. Wu*, L.P. Wang, N.Z. Hu, Y.Z. Hu, *Chinese Academy of Medical Sciences and Peking Union Medical College, China*
[P93]	**Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in animals** J. Ge*, X. Wang, L. Tao, Z. Wen, N. Feng, S. Yang, *Academy of Military Medical Sciences, China*
[P94]	**Rescue of recombinant peste des petits ruminants virus: Creation of a GFP-expressing virus and application in rapid virus neutralization test** Q. Hu[1,2], W. Chen*[1,2], K. Huang[2], M.D. Baron[1,3], Z. Bu[1,2], *[1]Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, China, [2]Nanjing Agricultural University, China, [3]Pirbright Laboratory, UK*
[P95]	**Recombinant canine distemper virus serves as bivalent live vaccine against rabies and canine distemper** X. Wang*[1], N. Feng[2], J. Ge[1], L. Shuai[1], L. Peng[1], Y. Gao[2], *[1]Chinese Academy of Agricultural Sciences, China, [2]Academy of Military Medical Sciences, China*

[P96]	**Generation and characterization of a new mammalian cell line continuously expressing virus-like particles of Japanese encephalitis virus for a second-generation subunit veterinary JEV vaccine** R.H. Hua*, Y.N. Li, Z.S. Chen, L.K. Liu, H. Huo, Z.G. Bu, *Harbin Veterinary Research Institute, China*
[P97]	**Cancer immunotherapy: Targeting tumors expressing mutant P53** B.S. Solomon, *Tel aviv University, Israel*
[P98]	**An *aroA* mutant of *Edwardsiella tarda*, a potential live and attenuated vaccine in olive flounder (*Paralichthys olivaceus*)** T.S. Jung*, S.B. Park, Y.R. Kim, *Gyeongsang National University, Republic of Korea*
[P99]	**Protective efficacy of a recombinant duck enteritis virus expressing H5N1 virus HA gene against the lethal H5N1 influenza virus change in commercial ducks and chickens** J.X. Liu*, P.C. Chen, L. Wu, *Harbin Veterinary Research Institute, China*
[P100]	**Generation and evaluation of the vaccine efficacy of a recombinant duck enteritis virus expressing truncated E and PrM proteins of duck tembusu virus** P.C. Chen*, J.X. Liu, L. Wu, Y.P. Jiang, Z.G. Bu, H.L. Chen, *CAAS, China*
[P101]	**Immunomodulating effect of different dual factor recombinant plasmids with porcine interferon-γ, interleukin-4 gene and CpG ODN on inactivated FMDV antigen in mice** Z.Z. Jing*, N. Zhao, G.H. Chen, X.B. He, Y.X. Fang, W.S. Li, *Lanzhou Veterinary Research Institute, CAAS, China*
[P102]	**Evaluation of residual virulence and protective efficacy afforded by Chinese Brucella melitensis strain M5-90 in mice, sheep and goats** S. Hu*, Z.J. Qiao, J.Z. Zhou, W.X. Liu, Z.G. Bu, *Chinese Academy of Agricultural Science, China*
[P103]	**Safety and potency of cell culture based antirabies vaccine produced in Ethiopia** A. Mengesha*, B. Hurisa, S. kerga, D. Bankovisky, A. Metlin, K. Urga, *Ethiopian Health and Nutrition Research Institite, Ethiopia*
[P104]	**A new multiepitope oral DNA vaccine delivered by salmonella typhi Ty21a against respiratory syncytial virus** F. Azizi Jalilian*[1], R. Amini[2], F. Jahanshiri[3], K. Yusoff[3], Z. Sekawi[3], *[1]Ilam University of Medical Sciences, Iran, [2]Hamadan University of Medical Sciences, Iran, [3]Univrsiti Putra Malaysia, Malaysia*
[P105]	**A new Oral DNA vaccine delivered by salmonella typhi *Ty21a* against respiratory syncytial virus infection** R. Amini*[1], F. Azizi Jalilian[2], F. Jahanshiri[3], K. Yusoff[3], Z. Sekawi[3], *[1]Hamadan University of Medical Sciences, Iran, [2]Ilam University of Medical Sciences, Iran, [3]Universiti Putra Malaysia, Malaysia*
[P106]	**Interchangeability of Quinvaxem® during primary vaccination schedules: Results from a phase IV, single-blind, randomized, controlled, single-centre study** M.R.Z. Capeding*[1], E. Alberto[1], C. Jica[2], A. Macura-Biegun[2], M. Rauscher[2], *[1]Research Institute for Tropical Medicine, The Philippines, [2]Crucell, Switzerland*
[P107]	**Immunogenicity optimization from recombinant vaccine Nucleoside hydrolase (NH36) of Leishmania (L.) donovani aade by a chimera compound of F1 And F3 peptides** D.C. Gomes, D. Nico, D.F. Feijó, C.B. Palatnik-de-Sousa*, *Universidade Federal do Rio de Janeiro, Brazil*
[P108]	***Taenia solium* taeniosis/ cysticercosis in africa: Risk factors, epidemiology and prospects for control using vaccination** E. Assana*, M.W. Lightowlers, A.P. Zoli, S. Geerts, *University of Ngaoundere, Cameroon*
[P109]	**A novel HIV DNA vaccine based on *Salmonella typhi* Ty21a bacterial ghosts** Y. Yang, J. Wen, G.Y. Zhao, Y. Guo, Z.H. Kou*, Y.S. Zhou, *Beijing Institute of Microbiology and Epidemiology, China*
[P110]	**A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus** C.Y. Wu*[1], Y.C. Yeh[1], J.T. Chan[1], Y.C. Yang[1], M.T. Liu[2], P.W. Hsiao[1], *[1]Academia Sinica, Taiwan, [2]Centers for Disease Control, Taiwan*
[P111]	**DNA immunization of broilers against H5N1 influenza virus** A. Stachyra*[1], R. Sawicka[1], V. Saczynska[2], B. Szewczyk[3], A. Gora-Sochacka[1], W. Zagorski[1], *[1]Institute of Biochemistry and Biophysics Polish Academy of Sciences, Poland, [2]Institute of Biotechnology and Antibiotics, Poland, [3]Faculty of Biotechnology University of Gdansk - Medical University of Gdansk, Poland*

[P112]	**Specific detection of hemagglutinin H5 from influenza A H5N1 virus by immunosensor based on gold electrode** U. Jarocka[1], R. Sawicka*[1], A. Stachyra[1], A. Porebska[2], V. Saczynska[2], B. Szewczyk[3], *[1]Polish Academy of Sciences, Poland, [2]Institute of Biotechnology and Antibiotics, Poland, [3]Medical University of Gdansk, Poland*
[P113]	**Enhanced heparin binding and reduced mouse neurovirulence by adaptive mutation E-Glu$_{345}$Lys of dengue type 4 virus in MRC-5 cells** H.H. Lin[1], H.C. Lee[1], H.J. Hsiao[1], M.J. Tsai[1], S.C. Wu*[1,2], *[1]National Tsing Hua Univ, Taiwan, [2]NHRI, NIIDV, Taiwan*
[P114]	**Broad neutralizing antibodies targeting a novel conserved region in HA1 of H5N1 influenza virus** L.D. Du*[1], Y.L. Li[1,2], J.G. Gao[2], Y.Z. Zhou[3], S.J. Jiang[1,4], *[1]New York Blood Center, USA, [2]Wenzhou Medical College, China, [3]Beijing Institute of Microbiology and Epidemiology, China, [4]Fudan University, China*
[P115]	**Porcine adenovirus-3 as a vaccine delivery vehicle** S.K. Tikoo, *University of Saskatchewan, Canada*
[P116]	**Differential involvement of TLR signaling in the generation of cellular and humoral immune responses following oral and parenteral immunization with Dukoral® vaccine** D. Sirskyj, J. Majithia, A. Azizi, A. Kumar*, *University of Ottawa, Canada*
[P117]	**Robust immunogenicity induced by HIV DNA vaccination with IL-12 plasmid adjuvant delivered via cellectra electroporation (EP) - preclinical and clinical results – The evolution of DNA vaccines** J. Yan[4], S. Kalams[2], N. Hutnick[1], M. Karuppiah[1], K. Broderick[4], D.B. Weiner*[4], *[1]University of Pennsylvania, USA, [2]Vanderbilt University, USA, [3]HVTN Trials Group, USA, [4]Inovio, USA*
[P118]	**Evaluation of the immune response in H5N1 AI vaccinated chickens** T.O. Erdene Ochir, *State Central Veterinary Laboratory, Mongolia*
[P119]	**Prospects, models and innovative technologies for immunization registries and tracking in developing countries** P.E. Kilgore, *Wayne State University, USA*